Paper: Using Functional Respiratory Imaging (FRI) to Compare Predicted Airway Deposition Between Pressurized Metered Dose Inhaler (pMDI) with AeroChamber Plus Flow-Vu ®️ Valved Holding Chamber (VHC) and Two Dry Powder Inhalers (DPIs) in a COPD patient
Dr Jason Suggett is a Pharmacist by training (in UK) who practiced in Hospital prior to completing a PhD in Pharmaceutics focusing on electrostatic charge of powders with specific reference to Dry Powder Inhalers. He has also completed an MBA.
His Pharmaceutical Industrial career covers more than 25 years, starting at 3M Health Care in the UK in the mid 90s where he worked within Inhalation Research & Development and Programme Management in managerial roles for nearly 10 years before joining IVAX / TEVA and working in both Global and European research & development and commercial roles. Jason then moved to Hovione FarmaCiencia in Portugal as Director of Pharma Operations responsible for all Drug Product Development with specific focus upon inhalation. He joined Trudell Medical International in 2012 as Group Director, Science and Technology, his group being responsible for New Product Development, Aerosol Science and Medical Affairs.
Throughout his career Dr Suggett has specialized in Inhalation Drug Delivery with expertise developed in MDI, DPI and Nebulized product development, including formulations, devices, clinical, registration and commercialization. He has coordinated a large number of clinical studies and has published extensively in the respiratory field.
Dr Suggett has also completed 10 years service on the USP, General Dosage Forms Expert Committee and Inhalation Sub-Committee.